depression

The Missouri hospital system designed its own 13-gene PGx panel, which it runs at its molecular genetics lab and calls the Kiddose PGx test.

The company sees a clearer path to clinical validation and reimbursement through molecules that more directly measure how drugs affect the brain.

The NeuroKaire test predicts a patient's drug response by combining patient-reported information, pharmacogenetics data, and so-called "brain-in-a-dish" functional testing.